Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus MECLOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus MECLOMEN.
CHILDREN'S ELIXSURE vs MECLOMEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: weakly inhibits cyclooxygenase (COX) in central nervous system, reduces prostaglandin synthesis, elevates pain threshold, and acts on hypothalamic heat-regulating center to lower body temperature. Chlorpheniramine: first-generation antihistamine; competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Dextromethorphan: noncompetitive NMDA receptor antagonist and sigma-1 agonist; suppresses cough by elevating threshold in medullary cough center. Pseudoephedrine: indirectly acting sympathomimetic; releases norepinephrine from presynaptic terminals, causing vasoconstriction and nasal decongestion.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
No established adult dose; product is specifically indicated for pediatric use only. Not recommended for adults.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal half-life: 4–6 hours in children with normal hepatic function; prolonged to >8 hours in hepatic impairment or overdose.
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
Renal elimination: ~90% as unchanged drug and active metabolite paracetamol glucuronide/sulfate conjugates; biliary/fecal: <5%.
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Category C
Category C
NSAID
NSAID